Accord Healthcare Recalls Levothyroxine Sodium Tablets, 100 mcg, Over Subpotency
The FDA's enforcement report lists a Class II recall of specific lots of the prescription thyroid drug, distributed nationwide, for a subpotent drug.
Every recalls & safety alerts report published for North Carolina, newest first.
The FDA's enforcement report lists a Class II recall of specific lots of the prescription thyroid drug, distributed nationwide, for a subpotent drug.
The FDA's enforcement report lists a Class II recall of 1000-count prescription bottles distributed nationwide, with the firm's database showing no other enforcement action.
FDA classifies nationwide recall of 112 mcg levothyroxine sodium tablets as Class II due to subpotent drug.
The FDA has closed the Class II recall of certain levothyroxine sodium tablets due to subpotency, according to an agency enforcement report.
FDA classifies recall of certain 200 mcg levothyroxine sodium tablets as Class II, citing subpotent drug.
FDA Class II recall of certain lots of Levothyroxine Sodium Tablets, 137 mcg, distributed nationwide.
The FDA enforcement report dated September 2, 2026, lists a Class II recall of a specific lot of levothyroxine sodium tablets due to subpotency.
FDA classifies recall of certain 150 mcg levothyroxine sodium tablets as Class II due to subpotency.
The FDA has closed the Class II recall of certain levothyroxine sodium tablets distributed nationwide.
The agency has closed the Class II recall of certain Veritas Standard Glenoid Baseplates, citing completed corrective action.
FDA Class II recall of two lots of levothyroxine sodium tablets distributed nationwide.
FDA Class II recall of certain 125 mcg levothyroxine tablets distributed nationwide.
FDA Class II recall of certain 25 mcg levothyroxine tablets distributed nationwide.
Liebel-Flarsheim Company LLC recalls 3,486 vials of Optiray Imaging Bulk Package-350 after FDA classifies action as Class I.
An ongoing Class I recall covers 498 burritos shipped to eight states due to undeclared soy.
An FDA enforcement report lists a nationwide recall by Chiesi USA, Inc. of two lots of the intravenous blood-pressure emulsion, with the reason given as "Lack of Assurance of Sterility."